

DEFINITION OF THE GENOMIC LANDSCAPE OF MASLD

NCT07249112

Status	RECRUITING
Phase	Not Applicable
Sponsor	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Enrollment	2,880 participants

Key Eligibility Criteria

Inclusion (10)

- Patients with advanced MASLD defined as liver fibrosis e2 and/or the development of HCC (Hepatocellular Carcinoma);
 - Patients enrolled in the context of the SERENA study and, where applicable, also in the context of the REASON study;
 - Liver biopsy for suspected Non-Alcoholic Steatohepatitis (NASH) at the time of diagnosis;
 - Cholecystectomies;
 - Age \[40-70 years\];
- ... and 5 more (see full listing online)

Exclusion (3)

- Positivity for chronic viral hepatitis (HCV-RNA and/or HBsAg);
- Positivity for other liver diseases such as autoimmune and viral hepatitis (Hepatitis B and C), hereditary hemochromatosis, alpha-1-antitrypsin deficiency, or Wilson's disease.
- Subjects with chronic degenerative diseases will be excluded, with the exception of well-controlled hypertension and Type 2 Diabetes Mellitus that does not require pharmacological therapy (as is already standard practice for blood donation eligibility). Also excluded are donors aged > 65 and < 40 years.

Locations (1 total)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Istituto di Ricovero e Cura a Carattere Scientifico di natura pubblica, Milan, Milano, Italy